Completed
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
NCT02658214
- Conditions
- Abdominal Neoplasms, Adenocarcinoma, Adnexal Diseases, +58 more
- Locations
-
- Research Site Chūōku, Japan
- Research Site Kashiwa, Japan
- Research Site Seoul, South Korea
- Research Site Seoul, South Korea